Xu Jialu, Zhu Ruimin, Chen Yiyu, Li Xin, Chen Xuequn, Liu Ming, Huang Yumeng
Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Department of Nephrology, Tianjin Third Central Hospital, Tianjin, China.
FASEB J. 2024 Dec 15;38(23):e70201. doi: 10.1096/fj.202401945R.
Chloroquine (CQ), initially introduced for the clinical treatment of malaria, has subsequently been found to exhibit beneficial effects in combating diabetes mellitus. The anti-hyperglycemic properties of chloroquine may be attributed to its anti-inflammatory response and its ability to activate the insulin signaling pathway. However, both animal and clinical studies have yielded mixed results. Moreover, the impact of chloroquine on pancreatic β-cells, the key player of glycemic control, was not known. To fill this knowledge gap, we investigated the effects of chloroquine on pancreatic β-cell functions. Our findings revealed that while chloroquine did not alter proinsulin expression, it interfered with the conversion of proinsulin to insulin, resulting in reduced insulin levels. Using multiple independent approaches, we further showed that chloroquine disrupted proinsulin oxidative folding in the endoplasmic reticulum (ER) and impaired proinsulin trafficking from ER to Golgi, leading to ER stress and decreased insulin production. Notably, the elevated ER stress observed in chloroquine-treated β-cells was reversed upon knockout of insulin genes, indicating that chloroquine-induced β-cell ER stress primarily through the accumulation of misfolded proinsulin, rather than directly affecting ER homeostasis. Further investigation into the mechanisms underlying chloroquine-induced proinsulin misfolding revealed that the accumulation of misfolded proinsulin was not caused by autophagy inhibition or the alkaline pH of chloroquine. Instead, it was primarily due to the disruption of the interaction between proinsulin and protein disulfide isomerase (PDI). Our findings unveiled new mechanisms of chloroquine treatment and raised important safety considerations regarding the use of chloroquine in diabetes treatment.
氯喹(CQ)最初用于疟疾的临床治疗,后来发现它在对抗糖尿病方面具有有益作用。氯喹的降血糖特性可能归因于其抗炎反应以及激活胰岛素信号通路的能力。然而,动物和临床研究都得出了喜忧参半的结果。此外,氯喹对胰腺β细胞(血糖控制的关键因素)的影响尚不清楚。为了填补这一知识空白,我们研究了氯喹对胰腺β细胞功能的影响。我们的研究结果表明,虽然氯喹不会改变胰岛素原的表达,但它会干扰胰岛素原向胰岛素的转化,导致胰岛素水平降低。我们使用多种独立方法进一步表明,氯喹破坏了内质网(ER)中胰岛素原的氧化折叠,并损害了胰岛素原从内质网到高尔基体的运输,导致内质网应激和胰岛素产生减少。值得注意的是,在敲除胰岛素基因后,氯喹处理的β细胞中观察到的内质网应激升高得到了逆转,这表明氯喹诱导的β细胞内质网应激主要是通过错误折叠的胰岛素原的积累,而不是直接影响内质网稳态。对氯喹诱导胰岛素原错误折叠的潜在机制的进一步研究表明,错误折叠的胰岛素原的积累不是由自噬抑制或氯喹的碱性pH值引起的。相反,这主要是由于胰岛素原与蛋白二硫键异构酶(PDI)之间相互作用的破坏。我们的研究结果揭示了氯喹治疗的新机制,并提出了关于在糖尿病治疗中使用氯喹的重要安全考虑因素。